"Visit the UCLA Health website for coronavirus updates."

During the past decade, UCLA Hematology/ Oncology- Pasadena conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 7 clinical trials were completed, i.e. on average, 233.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Hematology/ Oncology- Pasadena" #1 collaborator was "Medivation, Inc." with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Hematology/ Oncology- Pasadena" are "Metastatic Breast Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Cancer" (1 trials), "Melanoma" (1 trials) and "Metastatic Colorectal Carcinoma" (1 trials). Many other conditions were trialed in "UCLA Hematology/ Oncology- Pasadena" in a lesser frequency.

Most popular intervention types in "UCLA Hematology/ Oncology- Pasadena" are "Drug" (8 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Talazoparib" (2 trials), "Alclometasone cream" (1 trials), "Bevacizumab" (1 trials) and "Dacomitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Hematology/ Oncology- Pasadena" are 6 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA Hematology/ Oncology- Pasadena". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in UCLA Hematology/ Oncology- Pasadena, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Hematology/ Oncology- Pasadena, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".